CN114246896A

CN114246896A - A Chinese medicinal composition for treating hypertension, and its preparation method

Info

Publication number: CN114246896A
Application number: CN202210031014.4A
Authority: CN
Inventors: 卢芳; 刘树民; 刘涵星; 沙迪; 付佳琪; 王天雨; 袁晋
Original assignee: Heilongjiang University of Chinese Medicine
Current assignee: Heilongjiang University of Chinese Medicine
Priority date: 2022-01-12
Filing date: 2022-01-12
Publication date: 2022-03-29
Anticipated expiration: 2042-01-12
Also published as: CN114246896B

Abstract

The invention discloses a traditional Chinese medicine composition for treating hypertension and a preparation method thereof, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hypertension comprises the following raw materials in parts by weight: 10-25 parts of uncaria, 15-25 parts of salvia miltiorrhiza, 15-30 parts of kudzu root, 5-15 parts of eucommia bark, 5-15 parts of selfheal and 10-20 parts of radix achyranthis bidentatae. The uncaria is used for calming the liver and suppressing yang and calming endogenous wind; the salvia miltiorrhiza and the radix puerariae are used for activating blood and dissolving stasis and dredging blood vessels; eucommia bark is used for tonifying liver and kidney to prevent liver yin from being damaged; spica Prunellae can clear liver-fire, dissipate stagnation and relieve swelling; the achyranthes root is used together to dispel stasis and dredge channels, induce blood to descend and tonify liver and kidney. The components act together to achieve the effect of treating hypertension. Meanwhile, the invention also provides a preparation method of the traditional Chinese medicine composition, the disclosed preparation method is simple to operate, the quality control is easy to carry out in the production process, and the prepared traditional Chinese medicine composition is stable in chemical components.

Description

A Chinese medicinal composition for treating hypertension, and its preparation method

Technical Field

The invention relates to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating hypertension and a preparation method thereof.

Background

Hypertension, which belongs to the categories of vertigo, headache and the like in traditional Chinese medicine, accounts for more than 40% of the total death rate of cardiovascular and cerebrovascular diseases, and is one of the most major risk factors of cardiovascular and cerebrovascular diseases. Hypertension is a clinical syndrome characterized by elevated systemic arterial blood pressure (systolic pressure (SBP) is not less than 140mmHg, diastolic pressure (DBP) is not less than 90mmHg), and may be accompanied by functional or organic damage to heart, brain, kidney, etc. Hypertension generally has a slow onset of illness, is usually dizziness, headache, neck and neck tightness, fatigue, palpitation and the like, and only can cause blood pressure rise after fatigue, mental stress and mood fluctuation, and can recover to normal after rest. With the prolonged course of disease, the blood pressure is obviously and continuously increased, and various symptoms gradually appear. Poor long-term control of hypertension can cause structural and functional changes in the heart, such as left ventricular hypertrophy. In recent years, antihypertensive drugs have been developed rapidly, and there are more systematic treatment schemes in clinical, and there are five main classes of commonly used antihypertensive drugs: ACEI (angiotensin converting enzyme inhibitor), ARB (angiotensin receptor antagonist), CCB (calcium channel blocker), beta-receptor blocker and diuretic. But in fact, the treatment effect of the antihypertensive western medicine is not ideal, and only 39% of the hypertensive patients achieve the treatment goal that the blood pressure is lower than 140/90 mmHg. This leads people to turn to the traditional Chinese medicine treatment method, so the search for a treatment method and a medicine with definite clinical curative effect and little safe toxic and side effect is always concerned by the clinicians in various countries.

Disclosure of Invention

The invention aims to provide a traditional Chinese medicine composition for treating hypertension and a preparation method thereof. The traditional Chinese medicine composition is prepared by combining uncaria, salvia miltiorrhiza, kudzu root, eucommia bark, selfheal and achyranthes bidentata. The traditional Chinese medicine composition for treating hypertension can be prepared by the extraction process of the invention.

In order to achieve the purpose, the invention provides the following technical scheme:

the invention adopts one of the technical schemes: the traditional Chinese medicine composition for treating hypertension is prepared from the following raw materials in parts by mass:

10-25 parts of uncaria, 15-25 parts of salvia miltiorrhiza, 15-30 parts of kudzu root, 5-15 parts of eucommia bark, 5-15 parts of selfheal and 10-20 parts of radix achyranthis bidentatae.

Preferably, the traditional Chinese medicine composition for treating hypertension comprises the following raw materials in parts by weight: 10 parts of uncaria, 25 parts of salvia miltiorrhiza, 30 parts of kudzuvine root, 15 parts of eucommia bark, 15 parts of selfheal and 20 parts of achyranthes root.

Ramulus Uncariae cum uncis, which is derived from dried stem branch with hook of Uncaria rhynchophylla (Miq.) Miq.ex Havil; sweet taste and cool nature, enters liver and pericardium channels, and has the effects of calming wind, arresting convulsion, clearing heat and calming liver; modern researches have the effects of resisting epilepsy, tranquilizing, resisting mental dependence, lowering blood pressure, resisting cerebral ischemia, etc.

Saviae Miltiorrhizae radix derived from dried root and rhizome of Salvia milirhizorrhiza bge of Labiatae; bitter in taste and slightly cold in nature, and has the effects of invigorating blood circulation, removing blood stasis, dredging channels, relieving pain, clearing heart fire, relieving restlessness, cooling blood and resolving carbuncle; modern researches have the effects of improving blood rheological property, inhibiting blood coagulation and platelet functions, inhibiting thrombosis, improving coronary artery, improving myocardial ischemia, improving microcirculation, reducing blood lipid and resisting atherosclerosis, and also have the effects of tranquilizing, resisting anoxia, resisting oxidation, resisting bacteria, resisting inflammation, resisting tumor, promoting hepatocyte regeneration, resisting hepatic fibrosis, etc.

Kudzu root, derived from the dried root of Ohwi, Pueraria lobata (Willd.) Ohwi, a leguminous plant; sweet and pungent in taste, cool in nature, and has effects of expelling pathogenic factors from muscles and skin, relieving fever, promoting salivation, quenching thirst, promoting eruption, invigorating yang, relieving diarrhea, dredging meridian passage, and relieving alcoholism; modern research has the effects of relieving fever, dilating coronary artery, resisting myocardial ischemia, improving cardiac function, improving cerebral circulation, lowering blood pressure, inhibiting platelet aggregation, lowering blood sugar, reducing blood lipid, resisting oxidation, resisting tumor, etc.

Eucommia ulmoides, derived from dried bark of Eucommiaceae family plant Eucommia ulmoides Oliv; sweet taste and warm nature, enters liver and kidney meridians, and has the effects of nourishing liver and kidney, strengthening tendons and bones and preventing miscarriage; modern researches have the effects of lowering blood pressure, enhancing immunity, promoting bone cell proliferation, delaying aging, reducing blood lipid, relieving pain, tranquilizing mind, and resisting inflammation.

Prunellae Spica, which is derived from dried ear of Prunellae Spica (Prunella vulgaris L.) belonging to Labiatae; the tea is pungent and bitter in taste and cold in nature, enters liver and gallbladder channels, and has the effects of clearing liver-fire, improving eyesight, resolving hard mass and relieving swelling; modern researches have the effects of lowering blood pressure, resisting inflammation, inhibiting pathogenic bacteria, resisting tumor, lowering blood sugar, etc.

Achyranthis radix, derived from dried root of Achyranthus bidentis Bl. of Achyranthus of the family Achyranthes; the wine is bitter, sweet and sour in taste and neutral in nature, enters liver and kidney channels, and has the effects of removing blood stasis, stimulating the menstrual flow, tonifying liver and kidney, strengthening muscles and bones, inducing diuresis, treating stranguria and guiding blood downward; modern researches have the effects of exciting uterus, resisting fertility, resisting blood coagulation, diminishing inflammation, relieving pain, assimilating protein, delaying aging, enhancing immunity, enhancing memory and endurance, reducing blood sugar, inhibiting gastrointestinal smooth muscle, resisting virus, etc.

The traditional Chinese medicine considers that hypertension is mostly caused by liver-yang hyperactivity, kidney essence deficiency, qi and blood deficiency, turbid phlegm obstruction and blood stasis obstruction. In this disease, the principal deficiency indicates the invasion of pathogenic wind, fire, phlegm and blood stasis, while the deficiency indicates the deficiency of qi, blood, yin and yang, and the disharmony of liver and kidney is the basic pathological basis, and the disorder of qi and blood is the basic pathological change. The lesion part is mainly in the heart, liver and kidney, and the development and evolution law of the lesion part is usually manifested as the rising of liver fire and the hyperactivity of liver yang in the early stage; in the middle stage, yin deficiency and yang hyperactivity gradually develop into liver-kidney yin deficiency; in the later stage, yin deficiency involving yang often manifests as yin-yang deficiency and qi-blood imbalance accompanied by different degrees of phlegm and blood stasis, resulting in deficiency-excess mixed syndrome. Clinically, it is manifested as dizziness, headache, frequent onset of the disease, heavy head, light feet, tinnitus, palpitation, and high blood pressure.

The uncaria is used for calming the liver and suppressing yang and calming endogenous wind; the salvia miltiorrhiza and the radix puerariae are used for activating blood and dissolving stasis and dredging blood vessels; eucommia bark is used for tonifying liver and kidney to prevent liver yin from being damaged; spica Prunellae can clear liver-fire, dissipate stagnation and relieve swelling; the achyranthes root is used together to dispel stasis and dredge channels, induce blood to descend and tonify liver and kidney. The components act together to achieve the effect of treating hypertension.

The second technical scheme of the invention is as follows: the preparation method of the traditional Chinese medicine composition for treating hypertension is provided, and comprises the following steps:

step (1), carrying out reflux extraction on the salvia miltiorrhiza, the radix puerariae, the eucommia ulmoides, the selfheal and the radix achyranthis bidentatae which are soaked in the extracting solution, and filtering; repeating the above extraction steps on the filter residue, and filtering; mixing filtrates, and removing extractive solution to obtain extracts of Saviae Miltiorrhizae radix, radix Puerariae, Eucommiae cortex, Prunellae Spica, and Achyranthis radix;

step (2), mixing uncaria with the extracting solution, warm-soaking and filtering; repeating the warm soaking step on the filter residue, and filtering; mixing the filtrates, and removing the extractive solution to obtain ramulus Uncariae cum uncis extract;

and (3) combining the extracts of the salvia miltiorrhiza, the radix puerariae, the eucommia ulmoides, the selfheal and the radix achyranthis bidentatae obtained in the step (1) and the uncaria extract obtained in the step (2) to obtain the traditional Chinese medicine composition for treating hypertension.

Preferably, the material-to-liquid ratio of the salvia miltiorrhiza, the radix puerariae, the eucommia ulmoides, the prunella vulgaris, the radix achyranthis bidentatae and the extracting solution in the step (1) is 1g (8-12) mL; the extracting solution is ethanol water solution with the volume fraction of 60-80%; the soaking time is 0.5 h; the reflux extraction time is 1-2 h; the number of repetition of repeating the above extraction steps is 1-3.

More preferably, the reflux extraction is carried out while maintaining a slightly boiling state, that is, while maintaining the temperature at the surface of the extraction liquid, a small amount of bubbles are released.

Preferably, the material-liquid ratio of the uncaria and the extracting solution in the step (2) is 1g (8-12) mL; the extracting solution is ethanol water solution with the volume fraction of 60-80%; the temperature of warm dipping is 65-75 ℃, and the time is 1-2 h; the repetition frequency of the step of repeating the warm dipping is 1-3 times.

The third technical scheme of the invention is as follows: the traditional Chinese medicine oral preparation for treating hypertension comprises the traditional Chinese medicine composition for treating hypertension and pharmaceutically acceptable auxiliary materials.

Preferably, the dosage form of the traditional Chinese medicine oral preparation comprises granules, oral liquid, tablets, capsules or pills. More preferably granules and capsules.

The invention has the following beneficial technical effects:

the traditional Chinese medicine composition for treating hypertension provided by the invention takes uncaria and salvia miltiorrhiza as monarch drugs, radix puerariae, eucommia ulmoides and selfheal as ministerial drugs, and radix achyranthis bidentatae as an assistant and guide drug. The uncaria is used for calming the liver and suppressing yang and calming endogenous wind; the salvia miltiorrhiza and the radix puerariae are used for activating blood and dissolving stasis and dredging blood vessels; eucommia bark is used for tonifying liver and kidney to prevent liver yin from being damaged; spica Prunellae can clear liver-fire, dissipate stagnation and relieve swelling; the achyranthes root is used together to dispel stasis and dredge channels, induce blood to descend and tonify liver and kidney. The components act together to achieve the effect of treating hypertension.

The traditional Chinese medicine composition for treating hypertension provided by the invention is few in medicinal herbs, low in cost and small in toxic and side effects. The preparation process is simple to operate, the quality control is easy to carry out in the production process, and the chemical components of the prepared traditional Chinese medicine composition are stable as can be seen from the measurement result of a high performance liquid chromatograph. Pharmacological research experiment results show that the traditional Chinese medicine composition prepared by the extraction process provided by the invention can obviously reduce systolic pressure, diastolic pressure and heart rate, reduce the expression level of angiotensin II in serum, improve the expression level of NO in serum, reduce the quality index of the left ventricle of the heart, improve the functions of the heart and blood vessels, and has the effects of expanding blood vessels and reversing the hypertrophy of the left ventricle of the heart. The traditional Chinese medicine composition provided by the invention has determined and reliable curative effect and can be used for preparing the medicine for treating hypertension.

Detailed Description

Reference will now be made in detail to various exemplary embodiments of the invention, the detailed description should not be construed as limiting the invention but as a more detailed description of certain aspects, features and embodiments of the invention. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

Further, for numerical ranges in this disclosure, it is understood that each intervening value, between the upper and lower limit of that range, is also specifically disclosed. Every intervening value, to the extent any stated value or intervening value in a stated range, and any other stated or intervening value in a stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention.

As used herein, the terms "comprising," "including," "having," "containing," and the like are open-ended terms that mean including, but not limited to.

The sources of the traditional Chinese medicine and the kit used in the embodiment of the invention are as follows:

uncaria: hunan of the origin, Heilongjiang Xiishengtang pharmaceutical Co., Ltd, lot number 20200901;

red sage root: shandong, Heilongjiang Xiishengtang pharmaceutical Co., Ltd, Lot 20191001;

kudzu root: sichuan of origin, Heilongjiang Xiishengtang pharmaceutical Co., Ltd, lot number 20191001;

eucommia ulmoides: sichuan of origin, Heilongjiang Xiishengtang pharmaceutical Co., Ltd, lot number 20190901;

selfheal: anhui, Heilongjiang Xiisheng Tang pharmaceutical Co., Ltd., Lot No. 20190701;

achyranthes bidentata: henan of origin, Heilongjiang Xiishengtang pharmaceutical Co., Ltd., lot number 20200901;

angiotensin II assay kit, purchased from Jiangsu Jingmei Biotech limited, lot number 202109;

kit for measuring NO by one-step method, purchased from Nanjing institute of bioengineering, lot number 20211015.

The apparatus used in the embodiments of the present invention comprises:

ALC-NIBP non-invasive blood pressure measurement and analysis system (Shanghai Oercott Biotech limited); waters 2695 model high performance liquid chromatograph (USA); m200pro plate reader (Tecan, Switzerland); SY500 rotary evaporator (shanghai yanglong biochemical instrument factory); ALPHA1-4/LD-plus freeze dryer (christ, Germany); KDC-160HR high speed refrigerated centrifuge (Kyoho, K.K., Innovation Co., Ltd.); AL204 electronic balance (mettler-toledo instruments ltd).

Example 1

According to the orthogonal design of experiments method L₁₈(3⁶) The raw material ratios are screened, 6 traditional Chinese medicines are taken as 6 factors, each factor is provided with 3 levels of different dosages, the six-factor three-level orthogonal design is shown in table 1, the total amount of 18 test groups is shown in table 2, and the dosage of each group is shown in table 2.

TABLE 1 six-factor three-level orthogonal design table

Table 2 design of orthogonal experiments L₁₈(3⁶) Test group

The preparation steps of the traditional Chinese medicine composition for treating hypertension are as follows:

step (1): mixing weighed salvia miltiorrhiza, radix puerariae, eucommia ulmoides, selfheal and radix achyranthis bidentatae with 80% ethanol water solution according to the material-liquid ratio of 1g to 10mL, and soaking for 0.5 h;

step (2): heating and refluxing the soaked radix Salviae Miltiorrhizae, radix Puerariae, cortex Eucommiae, Spica Prunellae and radix Achyranthis bidentatae for 1.5h (keeping the solution slightly boiling during refluxing), and filtering; continuously adding 80% ethanol water solution into the filter residue, heating and refluxing for 1.5h (keeping the slight boiling state) in the same amount as the step (1), and filtering;

and (3): mixing the filtrates obtained in step (2), distilling off ethanol under reduced pressure by using a rotary evaporator, and then performing vacuum drying under reduced pressure to obtain extracts of radix Salviae Miltiorrhizae, radix Puerariae, cortex Eucommiae, Spica Prunellae, and radix Achyranthis bidentatae;

and (4): mixing the weighed uncaria with 80% ethanol water solution according to the material-liquid ratio of 1g to 10mL, heating to 70 ℃, soaking for 2h, and filtering; continuously adding 80% ethanol water solution into the filter residue, heating to 70 deg.C, soaking for 2 hr, and filtering;

and (5): mixing the filtrates obtained in step (4), distilling off ethanol under reduced pressure by using a rotary evaporator, and drying under reduced pressure and vacuum to obtain an uncaria extract;

and (6): and (3) uniformly mixing the extracts of the salvia miltiorrhiza, the radix puerariae, the eucommia ulmoides, the selfheal and the radix achyranthis bidentatae obtained in the step (3) and the uncaria extract obtained in the step (5) to prepare the traditional Chinese medicine composition for treating hypertension.

The effective components of the traditional Chinese medicine composition for treating hypertension prepared by each experimental group are measured by a high performance liquid chromatograph, and the measurement result is as follows: the preparation obtained from each group contains rhynchophylline in the range of 0.04-0.09%, isocoumarin in the range of 0.02-0.04%, tanshinone IIA in the range of 0.14-0.23% and puerarin in the range of 4.47-6.01%. The chemical components of the traditional Chinese medicine composition prepared by the invention are stable.

Comparative example 1

The prior document (application No. 201410294315.1) has a formula of a traditional Chinese medicine composition for treating hypertension, and the formula recorded in the prior document is compared with the formula of the traditional Chinese medicine composition for the comparative experiment, and the formula comprises the following specific components:

according to the weight parts, 12 parts of parasitic loranthus, 25 parts of kudzuvine root, 10 parts of ligusticum wallichii, 12 parts of wild chrysanthemum flower, 20 parts of selfheal, 7 parts of dogbane leaf, 25 parts of uncaria, 10 parts of gastrodia elata, 25 parts of salvia miltiorrhiza, 15 parts of radix achyranthis bidentatae, 17 parts of cortex moutan, 15 parts of tribulus terrestris and 20 parts of eucommia are prepared into a decoction by a traditional water decoction method, animal experiments and data acquisition are carried out according to the scheme of the embodiment 2, and the administration dosage is the same as that of the experiment group 3; the results are shown in tables 4 to 8.

Example 2

Evaluation of the efficacy of 18 groups of the Chinese medicinal compositions prepared in example 1 for treating hypertension and the decoction prepared in comparative example 1 for treating hypertension in rats of a model of hypertension induced by high salt

1. Test animal

SD (Sprague Dawley) rats, male, SPF grade, body weight (160-180 g), a total of 140, purchased from Liaoning Biotechnology GmbH, and bred in the center of laboratory animals of university of medicine, Heilongjiang, with license number SYXK (Black) 2018-. The animal of the study is approved by animal ethics committee of the university of traditional Chinese medicine of Heilongjiang under the approval number of 2020031203.

2. Method of producing a composite material

2.1 model preparation

The hypertension model caused by high salt is prepared by SD rats, a blank group is fed with conventional feed, a model group and an experimental group are fed with 8% high salt feed (7.5% NaCl + 92.5% conventional feed purchased from Guangdong province medical experimental animal center, No. Guangdong feed (2019)05073) in a mode of 1-18, the period lasts for 6 weeks, water is freely drunk, and the blood pressure is measured for 1 time every two weeks by an ALC-NIBP non-invasive blood pressure measurement and analysis system.

2.2 specific administration conditions for the laboratory animals

The blank group, the model group and each experimental group are 7 SD rats, and the intragastric volume per day is 0.5ml/100 g;

a blank group of SD rats is filled with equal volume of 0.9 percent normal saline;

model group high salt diet induced hypertension model SD rat gavage equal volume 0.9% normal saline;

experimental groups 1-18 high-salt diet induced hypertension model SD rats are perfused with equal volume of water dispersion solution of traditional Chinese medicine composition for treating hypertension prepared by corresponding experimental groups, and the administration dose is 2.25g/kg/d (according to crude drug concentration).

Comparative example 1 group of high salt diet induced hypertension model SD rats were gavaged with an equal volume of a diluent corresponding to the water decoction prepared in comparative example 1, and the administration dose was 2.25g/kg/d (in terms of crude drug concentration).

2.3 content determination of serum angiotensin II and NO

After the blood pressure is measured for the last time, after rats in each group are fasted and are not forbidden to be watered for 12 hours, 2% sodium pentobarbital is subjected to intraperitoneal injection anesthesia on the rats according to the dose standard of 50mg/kg, blood is taken from abdominal aorta, the abdominal aorta is kept still for 1 hour, centrifugation is carried out for 15 minutes at 3500r/min of 4 ℃, and supernatant is sucked and placed in a centrifuge tube to be stored in a refrigerator at minus 80 ℃ for standby. The content of angiotensin II and NO in the serum of rats in each group is detected by using an angiotensin II and NO kit.

2.4 left ventricular hypertrophy evaluation

After the abdominal aorta is completely bled, the rats are killed by decapitation, the chest cavity is opened by cutting the sternum along the xiphoid process, the heart is exposed and immediately picked up, the rats are cleaned by ice physiological saline, the left atrium and the right atrium are cut off along the atrioventricular ring after the water absorption paper is dried, the free wall of the right ventricle is cut off along the ventricular septum, the Left Ventricle Mass Index (LVMI) of each group of rats is weighed by an electronic balance, and the LVMI is the left ventricle mass (mg)/weight (g).

2.5 statistical treatment

SPSS 26.0 statistical software is used for data analysis, the measured data is expressed by Mean +/-standard deviation (Mean +/-SD), two-by-two comparison among groups is carried out by adopting one-factor variance analysis, the variance among the groups is detected by adopting an LSD (least squares) method, and the variance among the groups is detected by adopting Tamhane' sT2 (M). P <0.05 is statistically significant.

3 results

The change of systolic pressure and diastolic pressure, the change of heart rate and the content of serum angiotensin II before and after 4 weeks of administration of each experimental group are compared to carry out comprehensive scoring, the scoring ratio is the change of systolic pressure and diastolic pressure, the change of heart rate and the content of serum angiotensin II is 4:3:2:1, and the comprehensive scoring is calculated as

The specific results are shown in Table 3 below.

TABLE 3 composite score of Chinese medicinal composition

As can be seen from table 3, the experiment group 3 has the highest comprehensive score, i.e., the optimum mixture ratio is selected from 10 parts of uncaria, 25 parts of salvia miltiorrhiza, 30 parts of kudzuvine root, 15 parts of eucommia bark, 15 parts of prunella vulgaris and 20 parts of achyranthes bidentata by weight.

Further, the best experimental group as well as the comparative example 1 group were compared with the model group and the blank group:

the change of the systolic pressure of each group of rats before and after molding and after administration is shown in table 4; the diastolic pressure change conditions of the rats before and after molding and after administration are shown in Table 5; the heart rate changes of the rats before and after molding and after administration are shown in Table 6; the contents of angiotensin II and NO nitric oxide in the serum of each group of rats are shown in table 7; the left ventricular mass index of each rat heart is shown in table 8.

TABLE 4 variation of systolic blood pressure (mmHg) of rats before and after molding and after administration

Note: denotes P <0.05 compared to blank group; # denotes P <0.05 compared to model group; the following table is the same.

TABLE 5 diastolic pressure changes (mmHg) before and after molding and after administration for each group of rats

Group of	Before molding	After molding	The administration is carried out for 2 weeks	Administration for 4 weeks
					Blank group	91.05±7.70	92.92±9.43	92.47±5.38	92.43±5.48
Model set	99.52±9.28	125.62±4.79*	122.53±5.81	118.08±2.94
					Experimental group 3	95.19±5.93	125.28±3.45*	122.27±4.05	97.69±7.46#
Comparative example 1	94.22±6.37	125.05±4.16*	123.31±3.71	107.09±6.31#

As can be seen from tables 4 and 5, there was no significant difference in systolic and diastolic blood pressure in the rats of each group before molding (P > 0.05); after modeling, the systolic pressure and diastolic pressure of the model group, experimental group 3 and comparative group 1 rats were significantly increased (P <0.05) compared to the blank group; after 2 weeks of administration, the systolic and diastolic blood pressures of the rats of the experimental group 3 and the comparative group 1 were slightly decreased but not significantly different (P > 0.05) compared to the model group; after 4 weeks of administration, the systolic and diastolic blood pressure of the rats of the experimental group 3 and the comparative group 1 were significantly reduced and significantly different (P <0.05) compared to the model group.

TABLE 6 Heart Rate profiles (bpm) of rats before and after molding and after dosing

Group of	Before molding	After molding	The administration is carried out for 2 weeks	Administration for 4 weeks
					Blank group	396.90±14.96	393.17±15.00	391.23±26.36	390.48±14.23
Model set	404.14±41.88	432.56±16.64*	418.30±17.32	418.12±19.94
					Experimental group 3	400.29±16.97	414.47±23.57	404.29±9.32	382.91±14.02#
Comparative example 1	399.07±27.34	416.37±17.39	410.11±10.02	405.31±11.60#

As can be seen from Table 6, there was no significant difference in heart rate between the groups of rats before molding (P > 0.05); after modeling, compared with a blank group, the heart rate of the model group rats is obviously increased (P is less than 0.05), and the heart rate of the experimental group 3 and the heart rate of the comparative example 1 rats are not obviously different (P is more than 0.05); after 2 weeks of administration, the heart rate was slightly decreased but no significant difference (P > 0.05) between the experimental group 3 and the comparative example 1 rats, compared to the model group; after 4 weeks of administration, the systolic and diastolic blood pressure of the rats of the experimental group 3 and the comparative group 1 were significantly reduced and significantly different (P <0.05) compared to the model group.

TABLE 7 comparison of angiotensin II and NO-NO content in serum of rats of various groups

As can be seen from Table 7, the serum levels of angiotensin II (P <0.05) and NO (P <0.05) were significantly increased in the model group rats compared to the blank group; compared with the model group, the serum of the rats of the experimental group 3 and the comparative example 1 has obviously reduced angiotensin II content (P <0.05) and obviously increased NO content (P < 0.05).

TABLE 8 comparison of the left ventricular mass index of the hearts of rats in each group

Group of	Body weight (g)	Left ventricle mass (mg)	LVMI(mg/g)
				Blank group	432.97±20.26	670.37±42.28	1.55±0.07
Model set	445.96±28.47	804.50±45.38*	1.81±0.05*
				Experimental group 3	435.20±32.49	723.26±54.29#	1.67±0.11#
Comparative example 1	439.83±30.04	743.10±49.93#	1.69±0.09#

As can be seen from table 8, the cardiac left ventricular mass index LVMI of the model group rats was significantly increased compared to the blank group; the rats of the experimental group 3 and the comparative example 1 had significantly reduced cardiac left ventricular mass index LVMI compared to the model group.

The embodiment shows that the traditional Chinese medicine composition for treating hypertension, which is prepared by the invention, can obviously reduce systolic pressure, diastolic pressure and heart rate, obviously reduce the content of angiotensin II in serum, obviously increase the content of NO in serum and obviously reduce the LVMI (left ventricular mass index) of heart. The traditional Chinese medicine formula disclosed by the invention has the effects of reducing blood pressure, dilating blood vessels, improving cardiovascular function and reversing left ventricular hypertrophy. Compared with the comparative example 1, the systolic pressure of rats in the comparative example 1 is 151.39mmHg and the diastolic pressure is 107.09mmHg after 4 weeks of the gavage administration, the antihypertensive effect is lower than that of the composition of the invention, the systolic pressure is reduced to 135.31mmHg and the diastolic pressure is reduced to 97.69mmHg after 4 weeks of the gavage administration. The traditional Chinese medicine used by the composition has fewer medicinal herbs, lower cost and definite and reliable curative effect.

The above-described embodiments are merely illustrative of the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various modifications and improvements of the technical solutions of the present invention can be made by those skilled in the art without departing from the spirit of the present invention, and the technical solutions of the present invention are within the scope of the present invention defined by the claims.

Claims

1. A traditional Chinese medicine composition for treating hypertension is characterized by comprising the following raw materials in parts by weight: 10-25 parts of uncaria, 15-25 parts of salvia miltiorrhiza, 15-30 parts of kudzu root, 5-15 parts of eucommia bark, 5-15 parts of selfheal and 10-20 parts of radix achyranthis bidentatae.

2. The traditional Chinese medicine composition for treating hypertension according to claim 1, is characterized by comprising the following raw materials in parts by weight: 10 parts of uncaria, 25 parts of salvia miltiorrhiza, 30 parts of kudzuvine root, 15 parts of eucommia bark, 15 parts of selfheal and 20 parts of achyranthes root.

3. The method for preparing the traditional Chinese medicine composition for treating hypertension according to claim 1 or 2, which is characterized by comprising the following steps:

4. The preparation method according to claim 3, wherein the material-to-liquid ratio of the radix salviae miltiorrhizae, the radix puerariae, the eucommia ulmoides, the selfheal and the radix achyranthis bidentatae in the step (1) to the extracting solution is 1g (8-12) mL; the extracting solution is ethanol water solution with the volume fraction of 60-80%; the soaking time is 0.5 h; the reflux extraction time is 1-2 h; the number of repetition of repeating the above extraction steps is 1-3.

5. The preparation method according to claim 3, wherein the feed-liquid ratio of the uncaria rhynchophylla to the extracting solution in the step (2) is 1g (8-12) mL; the extracting solution is ethanol water solution with the volume fraction of 60-80%; the temperature of warm dipping is 65-75 ℃, and the time is 1-2 h; the repetition frequency of the step of repeating the warm dipping is 1-3 times.

6. A traditional Chinese medicine oral preparation for treating hypertension is characterized by comprising the traditional Chinese medicine composition for treating hypertension according to claim 1 or 2 and pharmaceutically acceptable auxiliary materials.

7. The oral traditional Chinese medicine preparation for treating hypertension according to claim 6, wherein the dosage form of the oral traditional Chinese medicine preparation comprises granules, oral liquid, tablets, capsules or pills.